IGF-1 LR3 is a synthetic analog of insulin-like growth factor-1 sold online mainly as a research-use peptide, not an FDA-approved medicine for human use. Chia does not offer IGF-1 LR3. If you are considering peptides for recovery, body composition, or longevity, use a licensed clinician rather than self-sourcing.
Wondering if NAD+ is right for you? Take the 3-min clinical quiz.
See if you qualify →Can you buy IGF-1 LR3 peptide for human use?
IGF-1 LR3 is sold by many online vendors, but those listings usually frame it as a laboratory research chemical, not a human medication. That distinction matters: a product sold for in vitro research is not the same as a prescribed medicine reviewed by a licensed clinician and dispensed by a pharmacy.
Why many online listings say “research use only”
Many IGF-1 LR3 vendors state that the compound is for laboratory research only and not for human or veterinary use 7. Some supplier pages also describe purity testing, identity testing, certificates of analysis, and storage rules, but that paperwork does not turn a research vial into a prescribed medication 7.
Why research peptides are different from prescribed medications
A prescribed medication involves a clinical reason for use, a health-history review, attention to contraindications, pharmacy standards, and follow-up. A research peptide supplier may be selling a chemical for lab use only; it is not evaluating your cancer history, blood glucose risk, kidney or liver disease, or other safety concerns.
What to avoid: human dosing claims, bodybuilding protocols, and unlabeled vials
Avoid any source that gives human dosing, cycling, reconstitution, injection, or “stacking” instructions for IGF-1 LR3. Those claims are not supported by FDA-approved labeling for IGF-1 LR3, and human clinical evidence for performance, recovery, and longevity uses is missing.
What is IGF-1 LR3?
IGF-1 LR3 stands for long arginine 3 insulin-like growth factor-1. It is a synthetic growth-factor analog related to native IGF-1, which is a hormone-like peptide involved in growth hormone signaling and tissue biology 1, 6.
What IGF-1 does in the body
Insulin-like growth factor-1, or IGF-1, is one of the main mediators of growth hormone, also called GH. A review of the IGF system describes IGF-1 as a 70-amino-acid peptide that supports growth in childhood and continues to have anabolic effects in adults 1.
IGF-1 is not just a “muscle signal.” It is part of a larger network that includes IGF-1 receptors, IGF-2 receptors, insulin-like growth factor binding proteins, and related proteins that affect cell growth, differentiation, survival, and apoptosis regulation 1.
What “LR3” means
Research-supplier descriptions use “LR3” to mean long arginine 3. These descriptions state that IGF-1 LR3 has an extended amino-acid sequence and an arginine substitution at the third amino-acid position, changes meant to alter how the molecule behaves in research systems 6, 8.
How IGF-1 LR3 differs from naturally occurring IGF-1
Native IGF-1 circulates mostly bound to insulin-like growth factor binding proteins, or IGFBPs. One review notes that about 98% of circulating IGF-1 is bound by IGFBPs, which strongly affects bioavailability and makes IGF-1 testing harder to interpret 1.
IGF-1 LR3 is described as having reduced binding to IGF-binding proteins in research settings, which may increase free receptor exposure compared with native IGF-1 8. That is also why medical supervision matters: more direct pathway activity may raise safety questions, especially when human data are sparse.
How does IGF-1 LR3 work in theory?
IGF-1 LR3 is discussed as a direct IGF-1 receptor agonist in research contexts. In plain English, that means it is designed to interact with the same receptor family involved in growth, repair, metabolism, and survival signaling 1.
IGF-1 receptor signaling
The IGF-1 receptor, or IGF-1R, is part of a signaling system involved in cell growth, survival, differentiation, and apoptosis regulation 1. Downstream pathways include PI3K/Akt, Raf/MEK/ERK, and mTOR-related signaling, which are normal parts of human biology but can also be relevant in disease states 1.
Growth hormone, liver IGF-1, and feedback loops
Growth hormone can stimulate the liver and other tissues to produce IGF-1. That upstream GH-to-IGF-1 pathway is different from giving a compound that is designed to act more directly on IGF-1 signaling 1.
This is one reason IGF-1 LR3 should not be lumped together with growth hormone-releasing peptides. For example, sermorelin is a growth hormone-releasing hormone analog used under clinician review, while IGF-1 LR3 is a downstream IGF-1 analog that Chia does not offer.
Why reduced binding-protein affinity matters
IGFBPs act like carrier proteins that shape how much IGF-1 is freely available to tissues. A compound designed to bind less strongly to IGFBPs may behave differently from native IGF-1, but that theoretical difference does not prove a safe or useful human treatment effect 1, 8.
What does the evidence show for IGF-1 LR3 in humans?
IGF-1 LR3 has limited human clinical evidence for body composition, muscle growth, fat loss, recovery, or longevity. Most patient-facing claims online are built from IGF-1 biology, research-market descriptions, or comparisons with different drugs, not from IGF-1 LR3 outcome trials.
What is known from IGF-1 biology
The IGF system is real and important. IGF-1 helps mediate growth hormone effects and participates in cell growth, differentiation, survival, and metabolic signaling 1.
But biology is not the same as proof of benefit. A pathway that supports normal tissue repair can also carry risks if pushed in the wrong person, at the wrong time, or without medical screening.
Why mecasermin data should not be treated as IGF-1 LR3 data
Mecasermin, sold as Increlex, is recombinant human IGF-1 approved for severe primary IGF-1 deficiency in specific pediatric patients 2. Its FDA labeling includes warnings about hypoglycemia, intracranial hypertension, tonsillar hypertrophy, slipped capital femoral epiphysis, and neoplasia concerns 2.
Those label facts do not make IGF-1 LR3 an approved drug, and they do not prove IGF-1 LR3 works for adults seeking muscle gain, fat loss, recovery, or longevity. Mecasermin and IGF-1 LR3 are different products with different regulatory status.
What is missing: human trials for muscle, fat loss, recovery, and longevity
For the claims people often search—more muscle, less fat, faster recovery, or longer life—the key missing piece is human outcome data for IGF-1 LR3. Without human trials, it is not possible to know the benefit-risk balance for those goals.
This matters because individual biology varies. IGF-1 signaling relates to glucose metabolism, growth pathways, and cancer biology, so benefits cannot be discussed honestly without also discussing risks and contraindications 1, 2.
What are the main safety concerns?
IGF-1 LR3 safety is uncertain because it lacks FDA-approved human-use labeling and robust human trials. The main concerns come from IGF-1 biology, the mecasermin label, and the known role of IGF signaling in glucose control and growth pathways 1, 2.
Blood sugar and insulin-like signaling
IGF-1 is insulin-like, and the FDA label for mecasermin warns about hypoglycemia, or low blood sugar 2. That is especially important for people with diabetes risk, insulin resistance, glucose-lowering medications, irregular meals, or symptoms that could overlap with low blood sugar.
Swelling, fluid retention, and nerve-type symptoms
Mecasermin labeling describes adverse reactions and warnings that include intracranial hypertension, lymphoid tissue hypertrophy, and other growth-related concerns 2. These are not IGF-1 LR3 trial results, but they show why growth-factor drugs need careful screening and follow-up.
Growth-factor pathway concerns, including cancer-related caution
The IGF-1 and IGF-1R pathway supports normal cell survival and proliferation, but it is also relevant to cancer biology because the same pathway can support survival and growth of malignant cells 1. Mecasermin labeling also includes neoplasia-related warnings 2.
Why medical history and lab review matter
A clinician review is not a formality. It is how a provider checks whether a peptide-related treatment fits your goals, medical history, medications, labs, and risk factors. People with cancer history, abnormal GH or IGF-1 levels, unexplained swelling, pregnancy, breastfeeding, cardiovascular disease, kidney disease, or liver disease should not self-source peptides.
How is IGF-1 LR3 different from prescribed or clinician-guided peptides?
IGF-1 LR3 is usually marketed online as a research-use peptide, while prescribed medications involve clinician review and pharmacy dispensing. The safer dividing line is not “peptide versus non-peptide”; it is licensed medical care versus no-prescription research-chemical sourcing.
Research-use peptide vs prescription medication
Research-use products are intended for lab settings, not self-injection or human dosing 7. A prescription medication is tied to a patient, a clinical purpose, and a provider who can review risks, interactions, side effects, and follow-up.
Compounded medication from a 503A pharmacy vs research chemical supplier
At Chia, eligible treatments are prescribed only when clinically appropriate after an online health questionnaire and licensed US provider review. When prescribed, medications are compounded in the US by state-licensed 503A pharmacies and shipped to the patient’s door; compounded medications are not FDA-approved.
| Option | What it is | Human evidence or FDA status | Key safety issues | Chia availability |
|---|---|---|---|---|
| IGF-1 LR3 | Synthetic IGF-1 analog, also called long arginine 3 insulin-like growth factor-1 | Not FDA-approved for human therapeutic use; human trials for body composition or longevity are lacking | Blood glucose effects, growth-factor pathway concerns, cancer-history caution, unknown long-term risk | Not offered by Chia |
| Mecasermin / Increlex | Recombinant human IGF-1 | FDA-approved for severe primary IGF-1 deficiency in specific pediatric patients 2 | Hypoglycemia, intracranial hypertension, lymphoid tissue hypertrophy, neoplasia warnings 2 | Not listed in Chia’s current catalog |
| Sermorelin | Growth hormone-releasing hormone analog | Clinician-guided peptide option; not the same as IGF-1 LR3 | Requires review of GH/IGF-1-related risks, symptoms, and medical history | Offered as sermorelin injection, nasal spray, and tablets |
| Tesamorelin | GHRH analog | FDA-approved for reduction of excess abdominal fat in HIV-associated lipodystrophy 4 | Can increase IGF-1, may affect glucose, contraindicated in active malignancy per labeling 4 | Not listed in Chia’s current catalog |
Does Chia sell IGF-1 LR3?
Chia does not sell IGF-1 LR3. We do not prescribe it, ship it, or present it as a human-use peptide option.
Chia does not offer IGF-1 LR3
If you searched “IGF-1 LR3 peptide buy,” the most important answer is simple: Chia is not a source for IGF-1 LR3. We also do not give IGF-1 LR3 dosing, cycling, reconstitution, injection, or stacking instructions.
Chia’s current peptide and longevity options that require clinician review
Chia’s current peptide and longevity options include sermorelin, NAD+, glutathione, and GHK-Cu. These are not substitutes for IGF-1 LR3, and each has its own evidence limits, safety questions, and eligibility review. When prescribed through Chia, compounded medications are dispensed by state-licensed 503A pharmacies and are not FDA-approved.
- Sermorelin: available through Chia as injection, nasal spray, and tablets; plans for injection and nasal spray currently start at $179/mo.
- NAD+: available through Chia as injection from $179/mo and nasal spray from $119/mo.
- Glutathione: available through Chia as injection or nasal spray, both currently from $179/mo.
- GHK-Cu: available through Chia as cream, currently from $159/mo.
- Foundation Longevity: a multi-treatment protocol with sermorelin injection, NAD+ injection, and glutathione injection, currently from $399/mo.
How online evaluation, eligibility review, and pharmacy fulfillment work at Chia
Chia care starts with a short online health questionnaire, then a licensed US provider reviews your information. A prescription is never guaranteed. If treatment is appropriate, medications are compounded by state-licensed 503A pharmacies and shipped to your door.
| Chia option | Available forms | How it differs from IGF-1 LR3 search results |
|---|---|---|
| Sermorelin | Injection, nasal spray, tablets | Clinician-reviewed growth hormone-releasing hormone analog; not a direct IGF-1 LR3 analog |
| NAD+ | Injection, nasal spray | Longevity-support medication option under provider review; not an IGF-1 receptor agonist |
| Glutathione | Injection, nasal spray | Antioxidant-related option under provider review; not a growth-factor analog |
| GHK-Cu | Cream | Skin-focused copper peptide option under provider review; not IGF-1 LR3 |
What should you do if you were searching for IGF-1 LR3 to buy?
Start with the goal, not the vial. If you were looking for IGF-1 LR3 for recovery, weight, energy, hormones, or longevity, the safer next step is a licensed medical evaluation instead of ordering a research chemical.
Clarify your goal: recovery, weight, energy, hormones, or longevity
Different goals call for different medical questions. Weight changes may need a metabolic review. Low energy may involve sleep, thyroid, anemia, hormones, medications, or nutrition. Recovery concerns may need injury evaluation, training-load review, or labs.
Do not self-dose research peptides
Self-dosing research peptides creates avoidable risk: uncertain sterility, uncertain identity, no clinician screening, no contraindication review, and no follow-up plan. For IGF-1 LR3 specifically, the concern is higher because the target pathway affects glucose, growth signaling, and cancer-related biology 1, 2.
Use a licensed provider for medical screening and safer alternatives
If you want to talk through peptide-related options Chia actually offers, you can start with the online eligibility quiz. A licensed provider reviews your health information and prescribes only when clinically appropriate; a prescription is not guaranteed.
No. IGF-1 LR3 is not FDA-approved as a medication for human therapeutic use. Online products are commonly labeled for research use only, which is not the same as a prescription medication.
Many online vendors sell IGF-1 LR3 as a research chemical, not for human use. Laws and policies can vary by context, but a research-use product should not be treated as a medicine for self-use.
No. IGF-1 LR3 is a modified analog of insulin-like growth factor-1. It is related to native IGF-1, but it has structural changes that are described as altering binding-protein interaction and research activity.
There is not strong human clinical trial evidence showing that IGF-1 LR3 safely builds muscle in people. Claims for bodybuilding, recovery, fat loss, or longevity should be treated with caution.
It may. IGF-1 biology is insulin-like, and approved recombinant IGF-1 labeling includes low blood sugar warnings. Anyone with diabetes risk or glucose-lowering medications should avoid self-sourcing and seek clinician review.
No. Chia does not sell, prescribe, or ship IGF-1 LR3.
Chia’s current peptide and longevity options include sermorelin, NAD+, glutathione, and GHK-Cu, depending on eligibility. These are clinician-reviewed options and are not substitutes for IGF-1 LR3.
Yes. You can complete Chia’s online eligibility quiz to share your goals and health history. A licensed provider reviews your information and prescribes only when clinically appropriate.
References
- 1.Baxter RC. Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports Anti-Doping. Diagnostics. 2021.
- 2.U.S. Food and Drug Administration. Increlex (mecasermin) prescribing information. 2023.
- 3.U.S. Food and Drug Administration. FDA approves Increlex for severe primary IGF-1 deficiency. 2005.
- 4.U.S. Food and Drug Administration. Egrifta SV (tesamorelin) prescribing information. 2024.
- 5.Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007.
- 6.Platinum Peptides. IGF1-LR3 Research Guide. 2026.
- 7.Palmetto Peptides Research Team. Buying IGF-1 LR3 Online for Research: Key Factors Researchers Should Consider. 2026.
- 8.Francis GL, Ross M, Ballard FJ, Milner SJ, Senn C, McNeil KA, Wallace JC, King R, Wells JR. Novel recombinant fusion protein analogues of insulin-like growth factor-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. Journal of Molecular Endocrinology. 1992.
- 9.Clemmons DR. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nature Reviews Drug Discovery. 2007.
- 10.Chia Health. Sermorelin product information. 2026.
- 11.Chia Health. Foundation Longevity protocol information. 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if NAD+ is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
